美康生物(300439.SZ):就體外診斷上游原材料研發等領域與博威生物達成合作意向
格隆匯10月21日丨美康生物(300439.SZ)公佈,公司於2021年10月20日與上海博威生物醫藥有限公司(“博威生物”)及其實際控制人王少雄簽署了合作備忘錄。各方本着“優勢互補、互惠雙贏、依法合規”的原則,公司將充分利用自身在體外診斷領域的優勢以及博威生物在CRO/CDMO領域的研發技術能力,擬進入CRO/CDMO領域,並在體外診斷行業上游原材料研發、生產等相關領域開展深入合作,實現合作共贏。
本次簽署合作備忘錄符合公司未來的戰略發展規劃,有利於集中各方優勢資源,圍繞公司在體外診斷上游原材料領域的核心技術、原料研發、生產等方面開展深度合作,能夠進一步加強公司原材料研發平台,從而逐步實現體外診斷產品中原材料的國產化,提升公司的綜合競爭力,符合公司及股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.